Literature DB >> 15051109

Long term therapy of generalized anxiety disorder.

Frédéric Rouillon1.   

Abstract

Generalized anxiety disorder (GAD) is a common (lifetime prevalence: 5.1%), recurrent condition, which often heralds other psychiatric disorders, notably depression. As by definition it is a disorder progressing over months, treatment should be designed on a long term basis. And yet, few studies have been conducted beyond the classical 6-8 weeks characterizing the acute treatment phase. This is especially true of anxiolytics, but also of antidepressants, with the exception of paroxetine and venlafaxine, which are the only drugs approved in this indication in Western countries. The efficacy of psychotherapy, notably relaxation and cognitive-behavioral therapy, is established in the treatment of GAD, but its preferred indications and possible combination with antidepressants are still to be specified. Long term, not to say very long term studies of GAD, as well as depression, will still be required in the future to improve its management and specify therapeutic modalities (combination treatment, optimal duration, continuous or intermittent therapy, choice of psychotherapeutic techniques or agents, em leader ). Early and adequately prolonged treatment should not only result in more numerous remission periods, but also in decreased frequency of co-morbidities whether depressive, addictive, or of another nature, and should also reduce the social impact of GAD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15051109     DOI: 10.1016/j.eurpsy.2004.01.001

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  2 in total

1.  Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter.

Authors:  K B Troelsen; E Ø Nielsen; N R Mirza
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

Review 2.  Can Long-Term Pharmacotherapy Prevent Relapses in Generalized Anxiety Disorder? A Systematic Review.

Authors:  Marina Dyskant Mochcovitch; Rafael Christophe da Rocha Freire; Rafael Ferreira Garcia; Antonio Egidio Nardi
Journal:  Clin Drug Investig       Date:  2017-08       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.